The Efficacy and Mechanism of Itraconazole in the Treatment of COPD Complicated with Pulmonary Fungal Infection
[Objective]To explore the therapeutic effect and possible mechanism of itraconazole in the treatment of chronic obstructive pulmonary disease(COPD)with fungal infection.[Methods]A retrospective analysis was con-ducted on the clinical data of 80 COPD patients with pulmonary fungal infections admitted to our hospital from Janu-ary 2019 to December 2021.According to different treatment methods,they were divided into the itraconazole group(treated with itraconazole)and the fluconazole group(treated with fluconazole),with 40 cases in each group.We compared the length of hospital stay,mortality rate,incidence of adverse reactions,and serum levels of tumor nec-rosis factor-α(TNF-α),interferon-y(IFN-γ),interleukin-1β(IL-1β),interleukin-2(IL-2),interleukin-4(IL-4),and interleukin-10(IL-10)before and after treatment between two groups.[Results]The hospitalization time of the itra-conazole group was shorter than that of the fluconazole group(P＜0.05),and the mortality rate was lower than that of the fluconazole group(P＜0.05).Before treatment,there was no statistically significant difference in serum levels of TNF-α,IFN-γ,IL-1β,IL-2,IL-4,and IL-10 between the two groups of patients(P＞0.05);After treat-ment,the serum levels of TNF-α,IL-2,IL-4,and IL-10 in the itraconazole group were lower than those in the flu-conazole group(P＜0.05),and the levels of IFN-γ were higher than those in the fluconazole group(P＜0.05);The incidence of adverse reactions in the itraconazole group was 30.00％,significantly lower than the 37.50％in the fluconazole group,and the difference was statistically significant(P＜0.05).[Conclusion]The use of itraconazole in the treatment of COPD patients with pulmonary fungal infection has a good clinical effect,and its possible mecha-nism of action is to regulate the level of inflammatory factors.
NETL
NSTL
万方数据
